Table 5.
Logistic regression model showing factors associated with clinically relevant fibrosis at end of study follow-up (N = 2419)
| APRI> 1.5 (clinically relevant fibrosis) at end of follow-up | ||||||
|---|---|---|---|---|---|---|
| Univariate Analysis | Multivariable Analysis | |||||
| Variable | OR | 95% CI | Wald p | OR | 95% CI | Wald p |
| Hepatitis B | ||||||
| Never co-infected | Reference | – | ||||
| Ever co-infected | 2.00 | 1.13–3.53 | 0.02 | |||
| Hepatitis C | ||||||
| Never co-infected | Reference | Reference | ||||
| Ever co-infected | 7.03 | 4.61–10.74 | < 0.0001 | 6.35 | 4.12–9.79 | < 0.0001 |
| Baseline AIDS | ||||||
| No ADI ever | Reference | |||||
| None before/at FARVDT | 1.72 | 0.69–4.31 | 0.41 | – | ||
| ≥ 1 before/at FARVDT | 1.95 | 0.73–5.19 | ||||
| Race | ||||||
| White | Reference | |||||
| Black | 0.28 | 0.12–0.65 | ||||
| Indigenous | 1.83 | 0.95–3.54 | ||||
| Asian | 0.77 | 0.33–1.84 | 0.009 | – | ||
| Hispanic | 0.51 | 0.16–1.67 | ||||
| Other | 1.00 | 0.35–2.84 | ||||
| Unknown | 1.31 | 0.78–2.18 | ||||
| Birth sex | ||||||
| Female | Reference | – | ||||
| Male | 0.69 | 0.43–1.10 | 0.12 | |||
| Province | ||||||
| BC | Reference | |||||
| ON | 0.44 | 0.28–0.70 | 0.0001 | – | ||
| QC | 0.34 | 0.17–0.67 | ||||
| Years on ARV | 0.97 | 0.92–1.02 | 0.26 | – | ||
| Age at first ARV | 1.01 | 0.99–1.02 | 0.21 | – | ||
| MSM | 0.34 | 0.26–0.60 | < 0.0001 | – | ||
| PWID | 5.05 | 3.37–7.56 | < 0.0001 | – | ||
| Baseline HIV viral load (Log10 copies/mL) | 0.17 | |||||
| < 4 | Reference | – | ||||
| 4–5 | 1.46 | 0.72–2.93 | ||||
| > 5 | 1.87 | 0.94–3.74 | ||||
| Follow-up HIV viral load (Log10 copies/mL) | ||||||
| < 4 | Reference | Reference | ||||
| 4–5 | 3.33 | 1.54–7.16 | < 0.0001 | 2.27 | 1.01–5.10 | < 0.0001 |
| > 5 | 8.80 | 4.41–17.43 | 7.33 | 3.46–15.51 | ||
| Baseline CD4 count (cells/mm3) | ||||||
| ≤ 100 | Reference | Reference | ||||
| 200–349 | 0.55 | 0.35–0.86 | 0.62 | 0.38–0.99 | ||
| 350–499 | 0.15 | 0.06–0.42 | 0.0001 | 0.18 | 0.07–0.51 | 0.004 |
| > 500 | 0.37 | 0.16–0.86 | 0.55 | 0.23–1.32 | ||
FARVDT first naïve ARV date, MSM Men who have Sex with Men, PWID People Who Infect Drugs
BC British Colombia, ON Ontario, QC Quebec
Variables considered in the multivariate model included: hepatitis B, hepatitis C, race, province, age at first ARV treatment, MSM, follow-up HIV viral load, baseline CD4 count. Due to co-linearity with hepatitis C, PWID was not included in the final model